April 19, 2024

Joint Pain Injections Market Size, Top Manufacturers Strategy by Industry Sales, Emerging Demands, Trends Analysis, Business Opportunity, Growth Strategy, and Forecast 2021-2030

In 2022, the joint pain injections market study by Precedence Research provides crucial information on market share, market size, growth rate analysis Y-O-Y, production, consumption, and sales analysis for the forecast period 2021 to 2030. The report contains 150+ pages with detailed analysis.

The global joint pain injections market size is forecasted to reach from US$ 4.16 billion in 2021 to US$ 7.59 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 6.9% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.

The joint pain injections market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1449

The geriatrics and the elderly are the most commonly affected by joint problems. The ripping of synovial fluid in the joints caused by injury or ageing causes joint discomfort. Hyaluronic acid, which is found in the synovial fluid, lubricates the spaces between the joints. Hyaluronic acid helps to reduce joint inflammation and pain caused by tissue deterioration and injury. During an injury, hyaluronic acid breaks down, causing joint discomfort and inflammation in the ligaments and tendons that surround the joint.

Osteoarthritis, which is caused by a loss of synovial fluid in the joint area, is a very frequent condition among the elderly. One of the joint pain injections contains hyaluronic acid and are injected directly into the joints to assist alleviate inflammation and pain by filling and lubricating the afflicted area. Psoriatic arthritis, bursitis, gout, osteoarthritis, and other types of joint discomfort are commonly treated with joint pain injections.

Scope of the Joint Pain Injections Market

Report CoverageDetails
Market Size In 2021USD 4.16 Billion
Growth Rate From 2021 to 2030CAGR of 6.9%
Revenue Projection By 2030USD 7.59 Billion
Largest MarketNorth America
Fastest Growing MarkletAsia Pacific
Segments Covered Injection Type, Distribution Channel, Region

Competitive Landscape Analysis:

Some of the leading companies operating in the joint pain injections market are profiled in the market study. The report also underscores winning strategies adopted over the last few years and gauges impact of the same on growth trajectory exhibited by the market over the last few years.

Major companies operating in this report are

  • Anika Therapeutics Inc.
  • Bioventus
  • Ferring Pharmaceuticals Inc.
  • Sanofi
  • Zimmer Biomet Holdings Inc.
  • Allergen Plc.
  • Pfizer Inc.
  • Chugai Pharmaceutical Co. Ltd
  • SEIKAGAKU Corporation
  • Ferring B.V.

Market Dynamics

Drivers

Increasing demand for hyaluronic acid injections

The injections segment for joint pain injections market is led by hyaluronic acid injection. Because human joints are like gears that are constantly subjected to wear and tear, hyaluronic acid has excellent lubrication and shock-absorbing properties similar to synovial fluid, reducing joint stiffness and tenderness. Because of its anti-inflammatory properties and ability to provide short-term relief in joint sprains experienced by athletes and industrial workers, corticosteroid injections are used as an adjuvant medication in joint pain. Thus, the increasing demand for hyaluronic acid injections is driving the growth of join pain injections market during the forecast period.

Restraints

Shortage of arthritis specialists

The arthritis is observed mainly in the old age people. The use of joint pain injections requires specialists. But due to lack of resources and knowledge, there is shortage of arthritis specialists in various regions. The shortage of arthritis specialists in developing and underdeveloped regions is one of the restricting factors for the growth of market. On the other hand, the high costs of arthritis injections also hinder the growth of the market. As a result, the shortage of arthritis specialists is expected to hinder the growth of joint pain injections market during the forecast period.

Opportunities

Growing geriatric population

The geriatric population is rapidly growing. According to the United Nations, more than 727 million people are 65 or older. Joint pain and other diseases are common among the elderly population. People aged 65 and up are not in good physical shape. They are unable to visit healthcare clinics and hospitals on a regular basis for health checks. As a result, joint pain injections can be used on a large scale by the geriatric population to avoid frequent hospital visits. As a result, during the forecast period, the growing geriatric population creates new lucrative opportunities for the growth of the joint pain injections market.

Challenges

Lack of awareness about the products

The people are not aware about the joint pain injections. The joint pain injections such as hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections. The use of these injections requires proper knowledge and training. The utilization of joint pain injections on patients is mainly done by doctors and healthcare experts. For this, the proper and training is provided to professionals. The lack of government initiatives for the promotion of joint pain injections is a restraint factor for the market. As a result, the lack of awareness about the products is a huge challenge for the growth of joint pain injections market during the forecast period.

Regional Snapshot

Asia-Pacific is expected to witness largest CAGR during the forecast period 2021 to 2030. Asia-Pacific dominates the global joint pain injections market due to rising healthcare expenditures and increased investments in the future years.

North America region accounted largest revenue share in 2020. Due to a huge patient pool and rising disease prevalence, an increase in the senior population, increased obesity, and a high adoption of innovative treatments for joint pain reduction in the region, North America region dominated the global joint pain injections market.

Segments Covered in the Report

By Injection Type

  • Corticosteroid Injections
  • Hyaluronic Acid Injections
  • Platelet-rich Plasma Injections
  • Placental tissue matrix (PTM) Injections

By Joint Type

  • Knee and Ankle
  • Hip
  • Shoulder and Elbow
  • Spinal Joints
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Product Type

  • Pre-filled injections
  • Vials

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Why should you invest in this report?

If you are aiming to enter the global joint pain injections market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for joint pain injections are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Purchase Full Research Report @ https://www.precedenceresearch.com/checkout/1449

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Joint Pain Injections Market 

5.1. COVID-19 Landscape: Joint Pain Injections Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Joint Pain Injections Market, By Product

8.1. Joint Pain Injections Market, by Product Type, 2021-2030

8.1.1. Pre-filled injections

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Vials

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Joint Pain Injections Market, By Injection

9.1. Joint Pain Injections Market, by Injection, 2021-2030

9.1.1. Corticosteroid Injections

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Hyaluronic Acid Injections

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Platelet-rich Plasma Injections

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Placental tissue matrix (PTM) Injections

9.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Joint Pain Injections Market, By Joint Type 

10.1. Joint Pain Injections Market, by Joint Type, 2021-2030

10.1.1. Knee and Ankle

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Hip

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Shoulder and Elbow

10.1.3.1. Market Revenue and Forecast (2019-2030)

10.1.4. Spinal Joints

10.1.4.1. Market Revenue and Forecast (2019-2030)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Joint Pain Injections Market, By Distribution Type 

11.1. Joint Pain Injections Market, by Distribution Type, 2021-2030

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2019-2030)

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2019-2030)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 12. Global Joint Pain Injections Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.2. Market Revenue and Forecast, by Injection (2019-2030)

12.1.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.1.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.1.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.1.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.7.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.8.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.7.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.8.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.7.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.8.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.5.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.5.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

Chapter 13. Company Profiles

13.1. Online Pharmacies

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bioventus

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Ferring Pharmaceuticals Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sanofi

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Zimmer Biomet Holdings Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Allergen Plc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Chugai Pharmaceutical Co. Ltd

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. SEIKAGAKU Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Ferring B.V.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1449

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →